SCHEMBL4039240

SCHEMBL4039240

CN1CCN(C(=O)c2ccc(-n3nc(Nc4ccc(N5CCOCC5)cc4)nc3N)nc2)CC1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 10/20 0.63
KIT P10721 7/20 0.63
ALDH1A1 P00352 2/20 0.49
AXL P30530 3/20 0.49
IRAK4 Q9NWZ3 3/20 0.47
AURKA O14965 2/20 0.47
KDM4E B2RXH2 1/20 0.47
POLB P06746 1/20 0.47
HPGD P15428 1/20 0.47
ALOX15 P16050 1/20 0.47
HSD17B10 Q99714 1/20 0.47
JAK2 O60674 4/20 0.46
LRRK2 Q5S007 1/20 0.46
PIK3CA P42336 3/20 0.45
MTOR P42345 2/20 0.45
PIK3CG P48736 2/20 0.45
INSR P06213 2/20 0.45
CDK4 P11802 1/20 0.44
CCNA2 P20248 1/20 0.44
CDK2 P24941 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4038186 0.94 FLT3 (0.70) FLT3KITALDH1A1AXLIRAK4
SCHEMBL13963542 0.90 FLT3 (0.63) FLT3KITALDH1A1AXLIRAK4
SCHEMBL12780326 0.87 KIT (0.67) FLT3KITIRAK4AURKAJAK2
SCHEMBL4037659 0.86 FLT3 (0.66) FLT3KITAXLIRAK4AURKA
SCHEMBL13963543 0.81 FLT3 (0.59) FLT3KITAXLIRAK4AURKA
SCHEMBL12780341 0.81 KIT (0.71) FLT3KITIRAK4AURKAJAK2
SCHEMBL4040681 0.80 FLT3 (0.70) FLT3KITAXLIRAK4AURKA
SCHEMBL4039007 0.80 FLT3 (0.58) FLT3KITAXLIRAK4AURKA
SCHEMBL12780334 0.79 KIT (0.68) FLT3KITALDH1A1IRAK4AURKA
SCHEMBL4046489 0.77 FLT3 (0.64) FLT3KITAXLIRAK4AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
EP-1562589-B1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2009-01-07 EP disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K1, MAP3K5 FLT3 220/4885KIT 1144/4885ALDH1A1 3235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.